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Abstract
Objective: Nitric oxide synthase is the key enzyme of the conversion of 
L-arginine to L-citrulline and nitric oxide. We conducted a study to investi-
gate the association between positive inducible nitric oxide synthase (iNOS) 
mRNA expression and recurrence of bladder cancer.
Patients and Methods: Seventy-one patients with primary non-muscle-
invasive bladder cancer were enrolled in this study. Tumor tissues were 
harvested during transurethral resection of bladder tumors. All operations 
were performed at the same hospital. Recurrence-free patients were fol-
lowed up for at least 1 year unless tumors recurred during that time. The 
median intervals of follow-up were 34 months in the recurrence-free group 
and 12 months in the recurrence group. iNOS mRNA was detected using the 
RT-PCR-based method.
Results: Bladder cancer patients with positive iNOS mRNA expression had 
a higher recurrence risk (18.7% vs. 2.6%; p= 0.04). After adjusting for 
other risk factors, a statistical significance remained (p= 0.04; hazards 
ratio = 13.27; 95% CI = 1.07–164.36). The patients also had reduced 
recurrence-free survival (p= 0.019).
Conclusion: The positive expression of iNOS mRNA may be a useful prog-
nostic indicator of bladder cancer. [Tzu Chi Med J 2008;20(2):119–124]
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1. Introduction
The incidence of bladder cancer was ranked tenth 
among all cancer cases in Taiwan in 2000 [1]. Signifi-
cantly higher incidence rates of bladder cancer, 26.1% 
in men and 21.1% in women per 100,000 persons, 
have been observed in the endemic area of blackfoot 
disease (BFD) in southern Taiwan [2,3]. Bladder cancer 
is a common urological malignancy with a recurrence 
rate of approximately 70% [4].
Nitric oxide synthase (NOS) is the key enzyme for 
the conversion of L-arginine to L-citrulline and nitric 
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oxide (NO) [5,6]. The NOS family consists of endothe-
lial, neuronal, and inducible nitric oxide synthases 
(eNOS, nNOS, and iNOS, respectively) [7]. iNOS genes, 
located on the human chromosome 17, can be induced 
by lipopolysaccharide, cytokines in macrophages, or 
tumor-related immune reactions [8–10]. Swana et al 
reported that iNOS was detected in human bladder 
cancer tissues but not in normal bladder tissues, and 
that it was found in macrophages and neutrophils of 
bladder cancer tissues and some tumor cells [11]. To 
our knowledge, only one group of researchers has in-
vestigated the association between iNOS and bladder 
cancer recurrence, demonstrating a high but not sig-
nificant risk of recurrence among patients with iNOS 
expression [12]. Therefore, the aim of this study was to 
elucidate the association between iNOS messenger 
ribonucleic acid (mRNA) expression and the recurrence 
of bladder cancer.
2. Patients and methods
2.1. Patients and tissue collection
From November 2000 through December 2003, pa-
tients with primary non-muscle-invasive bladder cancer 
were enrolled. These cases were newly diagnosed and 
pathology was confirmed. Patients who had combined 
urothelial tumors in the upper urinary tract were ex-
cluded. Tumor tissues were harvested by transurethral 
resection of bladder tumors (TURBT) performed at a 
single hospital. Specimens were immediately frozen in 
liquid nitrogen after TURBT, and were stored at −86°C
in a tissue bank. Representative sections of each fro-
zen block were embedded in paraffin and stained with 
hematoxylin-eosin. All specimens were graded accord-
ing to a modification of the World Health Organization 
classification and pathological staging was based on 
the TNM pathological staging system [13,14]. All pa-
tients received weekly bacillus Calmette-Guerin (BCG) 
intravesical immunotherapy for 6 weeks. There was no 
perioperative intravesical chemotherapy. All patients 
underwent cystoscopy and urine cytology every 3 
months for 24 months after the initial tumor resection, 
every 6 months for 2 years following that, and annually 
thereafter [15]. All recurrence-free patients were fol-
lowed up for at least 12 months unless tumors recurred 
during that time. The study was approved by the Ethics 
Committee of the participating hospital.
2.2. RNA isolation
The size of each specimen was approximately 1 cm3.
The RNA isolation system (Biotecx Laboratories Inc., 
Houston, TX, USA) was applied as previously de-
scribed [16]. RNA concentrations were determined 
using spectrophotometric analysis (1 OD of A260 equal 
to 40 µg/mL RNA). The purity of extraction was as-
sessed using the A260/280 ratio, which was > 1.7 in 
all specimens.
2.3. Reverse transcriptase-polymerase 
chain reaction (RT-PCR) with 
human iNOS primers
Single-strand complementary DNA (cDNA) was syn-
thesized using oligo-dT priming of 2 µg of total RNA 
with 1 µL (200 U/L) Superscript II reverse transcriptase 
(Promega Inc., Madison, WI, USA) for 1 hour at 42°C,
and then the reaction was stopped by denaturation at 
70°C for 15 minutes. The primer pairs used were the 
sense primer 5’-ATTCACTCAGCTGTGCATCG-3’ and the 
antisense primer 5’-CAGCATACAGGCAAAGAGCA-3’. 
RT-PCR yielded 730-bp fragments. Controls for cDNA 
synthesis were β-actin specific primers and generated 
307-bp of PCR product. Positive iNOS controls were 
from human liver cells [11]. As a negative control, PCR 
was performed in the absence of primers and in the 
absence of cDNA. An amplification reaction was car-
ried out using one-tenth of the reverse-transcribed RNA, 
Taq polymerase buffer containing 200 µmol/L deoxy-
nucleotide triphosphate (dNTP), 1 U DyNAzyme II DNA 
Polymerase (Finnzymes Inc., Finland), and 10 µM of a 
pair of iNOS primers. PCR was performed for 35 cycles 
with denaturation at 94°C for 1 minute, annealing at 
56°C for 1 minute, and extension at 72°C for 1 minute. 
Amplified products and 0.1 µg GeneRuler 100 bp DNA 
Ladder (MBI Ferments, Lithuania) were electrophoresed 
on 1.2% agarose gels, and stained with ethidium bro-
mide. All gels were photographed with the ImageMaster 
VDS video imaging system (Amersham Pharmacia 
Biotech Inc., Piscataway, NJ, USA), and documented 
using LISCAP Image Capture Software, version 1.0 
(Amersham Pharmacia Biotech Inc.). At least two re-
peated analyses were carried out for each tissue. Each 
gel picture was read by two researchers.
2.4. Statistical analysis
iNOS mRNA expression was denoted as positive or 
negative. The χ2 and Fisher’s exact tests were applied 
to calculate the association between the recurrence of 
bladder cancer and the risk factors (gender, age, en-
demic area of BFD, tumor grade, tumor stage, iNOS 
mRNA expression). Additionally, Kaplan-Meier product 
limit estimates of survival and log-rank tests were used 
to analyze the data between iNOS expression and 
disease-free months before recurrence. Multivariate 
analysis was done using Cox’s proportional hazard re-
gression. The level of statistical significance was set at 
p< 0.05 (two-sided). SPSS statistical package version 
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9.0 (SPSS Inc., Chicago, IL, USA) was used for the 
analyses.
3. Results
At the endpoint of the study, a total of 78 specimens 
from seven cases with recurrence and 64 recurrence-
free cases were obtained. Medians for the duration 
of follow-up were 12 months (range, 4–32 months) 
in the recurrence group and 34 months (range, 
12–49 months) in the recurrence-free group. Overall 
age at the first diagnosis was 67.9 ± 12.5 years 
(mean± standard deviation). Table 1 shows increased 
recurrence risks among the men (12.5% vs. 4.3%), 
the elderly (13% vs. 4%), those with high grade tu-
mors (50.5% in high grade vs. 8.7% in low grade), 
and those with stage Ta (13.6% in Ta vs. 3.7% in 
T1), as well as those in whom iNOS mRNA expres-
sion was detected (18.7% vs. 2.6%). Positive iNOS 
mRNA expression was the only risk factor that 
reached a significant difference (p= 0.04).
Among the 13 residents from the BFD endemic 
area, a high risk population for bladder cancer [3], 
only one (7.7%) developed recurrence of bladder 
cancer. No association was shown between being a 
resident of the BFD endemic area and recurrence of 
bladder cancer (p= 0.77; Table 1).
Multivariate analysis revealed that patients with high 
grades of bladder cancer had higher recurrence risks 
(p= 0.057; hazards ratio = 17.28; 95% CI = 0.92–325.23; 
Table 2).
iNOS mRNA expression was detected in 45.1% 
(32/71) of patients. Recurrence of bladder cancer was 
found in six (18.7%) patients with positive iNOS mRNA 
expression and one (2.6%) patient without positive 
results. A significant difference was shown between the 
two groups (p= 0.04; Table 1). For each patient with 
recurrent cancer, the RT-PCR product levels were con-
sistent during the first diagnosis and recurrent tumor 
tissues. After adjusting for age, gender, BFD, and tumor 
grade, a statistical significance was reached (p= 0.044; 
hazards ratio = 13.27; 95% CI = 1.07–164.36; Table 2). 
In addition, patients with positive expressions of iNOS 
mRNA had reduced recurrence-free survival (p= 0.019; 
Fig. 1).
Calculating the data from Table 1, the sensitivity of 
positive expression of iNOS mRNA to predict the recur-
rence of bladder cancer was 85.7%, and the specificity 
was 59.4%.
4. Discussion
The present study was designed to identify the asso-
ciation between positive iNOS mRNA expression and 
Table 1 — Relationship between various risk factors and recurrent bladder cancer*
 Bladder cancer (n= 7) Recurrence (n= 64) 
p
 Yes No
Age (yr)   0.42
≥ 65 6 (13.0) 40 (87.0)
< 65 1 (4.0) 24 (96.0)
Gender   0.41
  Male 6 (12.5) 42 (87.5)
  Female 1 (4.3) 22 (95.7)
Live in BFD endemic area   0.77
  Yes 1 (7.7) 12 (92.3)
  No 6 (10.3) 52 (89.7)
Tumor cell type
  Transitional 7 (100) 64 (100)
  Non-transitional 0 (0) 0 (0)
Tumor stage   0.17
  Tis 0 (0) 0 (0)
  Ta 6 (13.6) 38 (86.4)
  T1 1 (3.7) 26 (96.3)
Tumor grade   0.19
  Low 6 (8.7) 63 (91.3)
  High 1 (50.0) 1 (50.0)
iNOS mRNA expression   0.04
  Positive 6 (18.7) 26 (81.3)
  Negative 1 (2.6) 38 (97.4)
*Data presented as n (%). BFD = blackfoot disease.
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the recurrence of bladder cancer. From our data, 
bladder cancer patients with positive iNOS mRNA ex-
pression had higher recurrence risks and reduced 
recurrence-free survival.
Some researchers reported that NOS was detected 
in malignant diseases, such as prostate cancer, gyne-
cological cancer and breast cancer [17–19], and iNOS 
was not detected in those with colorectal cancer [20]. 
Only a few studies have provided evidence of the 
association between bladder cancer and iNOS or 
iNOS mRNA [10,11,21–24]. Moreover, only one pub-
lished report included the recurrence of bladder cancer 
and iNOS [12].
Previously, researchers reported various detection 
rates of iNOS mRNA or iNOS in patients with primary 
bladder cancer, ranging from 50% to 100% [10–12, 
22–24]. The results of our study showed that iNOS 
mRNA expression was detected in 45.1% of all bladder 
cancer patients. Most of the results from previously 
published studies had small sample sizes. In the study 
by Sandes and colleagues, 21 patients who were 
followed-up for 2 years had a rate of positive iNOS ex-
pression of 50% [12]. This detection rate was similar 
to our data.
The investigation by Sandes et al revealed that re-
currences were found in 80% of subjects with positive 
iNOS and 27% of iNOS-negative patients [12]. In our 
study, recurrence rates (18.7% and 2.6%, respectively) 
were far lower than their’s. However, we agree that pa-
tients with positive iNOS expression have markedly 
increased risks of recurrence of bladder cancer.
Based on the results of studies investigating bladder 
cancer and other malignancies, tumorigenesis of NO 
depends on the local concentrations [18,25–27]. 
Generally speaking, high concentrations of NO can 
cause tumor cell apoptosis. An example is provided by 
BCG immunotherapy for non-muscle-invasive bladder 
cancer patients. BCG can induce iNOS activity through 
certain cytokines in rat bladders [28]. For example, a 
patient who received BCG intravesical therapy produced 
a 30-fold increase of gaseous NO in his bladder 
[21,29].
On the other hand, low levels or deficiency of NOS 
activity can induce tumorigenic action such as neovas-
cularity [10,17]. For example, iNOS is not found in pa-
tients with colon cancer [30]. Thomsen et al showed 
that the concentration of NO generated by NOS in vivo
was too low to cause apoptosis and cytotoxicity [17]. 
The results of other studies pointed out that tumor 
angiogenic factors, such as vascular endothelial growth 
factor, requires NO/guanylate cyclase/cyclic guanosine 
monophosphate (cGMP) pathway to promote neovas-
cular growth [31–35]. Lin et al reported higher micro-
vessel density in bladder cancer tissues with positive 
iNOS than in tissues with negative iNOS [10]. These 
findings support that iNOS and NO promote tumor 
angiogenesis through the NO/cGMP pathway.
Becker found that tumor cells produced cytokines, 
such as interleukin (IL)-4 and IL-10, to suppress the 
NOS gene, and could be induced by interferon-γ, OK432 
and lipopolysaccharide [36]. The hypothesis demon-
strated that a low concentration of NO was modu-
lated by tumor-related immunoactivity and inhibited 
apoptosis in tumor cells.
As shown in the discussion above, the presence of 
NOS activity caused anti- or pro-tumor action by its ac-
tivity level. Based on our qualitative data of the RT-PCR 
product, we did not find evidence to clarify the relation-
ship between tumor recurrence and levels of iNOS 
activity. Larger quantitative studies are necessary to 
Table 2 — Multivariate analysis of the association of various risk factors and recurrence of bladder cancer
Variable Classification p HR (95% CI)
Age (yr) ≥ 65 vs.< 65 0.706 1.42 (0.17–14.29)
Gender Male vs. Female 0.389 2.60 (0.30–22.75)
Live in BFD endemic area Yes vs. No 0.604 0.50 (0.04–6.85)
Tumor grade High vs. Low 0.057 17.28 (0.92–325.23)
iNOS mRNA expression Positive vs. Negative 0.044 13.27 (1.07–164.36)
HR = hazards ratio, estimated by Cox’s proportional hazard model and adjusted for age, gender, resident of BFD endemic area, tumor grade, and 
iNOS mRNA; CI = confidence interval; BFD = blackfoot disease.
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Fig. 1 — Recurrence-free survival of non-muscle-invasive 
bladder cancer patients with and without iNOS mRNA 
expression. A significant difference was reached (p= 0.019, 
log-rank test).
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investigate the relationship. Additionally, because 
higher recurrence risks were observed in the group 
with positive iNOS mRNA expression, these cases will 
be intensively followed.
In the present study, the recurrence rate was 9.86% 
for patients with bladder cancer treated using TURBT 
and BCG intravesical immunotherapy. Previous re-
searchers demonstrated that BCG reduced tumor re-
currence rate to 11–27% in those with TURBT and BCG 
immunotherapy [37]. However, the rate was not relia-
ble in a small size study. Our lower recurrence rate 
(3.7%) in stage T1 may be attributed to the small size 
and to chance.
5. Conclusion
Bladder cancer patients with positive expression of 
iNOS mRNA had higher recurrence risks of bladder 
cancer and reduced recurrence-free survival. Positive 
iNOS mRNA expression may be a useful prognostic 
indicator of bladder cancer.
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